0,05. Доказательная медицина от магии до поисков бессмертия — страница 38 из 43

Counsell C. E., Clarke M. J., Slattery J. et al. The miracle of DICE therapy for acute stroke: fact or fictional product of subgroup analysis? // BMJ. 1994. Vol. 309. P. 1677–1681.

Konstam M. A., Weir M. R., Reicin A., Shapiro D., Sperling R. S., Barr E., Gertz B. J. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib // Circulation. 2001. November 6. Vol. 104. № 19. P. 2280–2288.

De Leon J. Evidence-based medicine versus personalized medicine: are they enemies? // Journal of Clinical Psychopharmacology. 2012. April. Vol. 32. № 2. P. 153–164.

Ioannidis J. P. The mass production of redundant, misleading, and conflicted systematic reviews and meta-analyses // The Milbank quarterly. 2016. September. Vol. 94. № 3. P. 485–514.

Samet J. M. Epidemiology and the tobacco epidemic: how research on tobacco and health shaped epidemiology // American Journal of Epidemiology. 2016. March 1. Vol. 183. № 5. P. 394–402.

Cochrane A. Sickness in Salonica: my first, worst, and most successful clinical trial // British Medical Journal. 1984. December. Vol. 289. P. 1726–1727.

Simpson G. G. The therapiste and the researcher // Science. 1967. October 13. Vol. 158. № 3798. P. 246.

Cochrane A. L. Effectiveness and efficiency. London: Nuffield Provincial Hospitals Trust, 1972.

Stavrou A., Challoumas D., Dimitrakakis G. Archibald Cochrane (1909–1988): the father of evidence-based medicine // Interactive cardiovascular and thoracic surgery. 2014. January. Vol. 18. № 1. P. 121–124.

Barron A. B., Maleszka R., Helliwell P. G., Robinson G. E. Effects of cocaine on honey bee dance behaviour // The Journal of Experimental Biology. 2009. Vol. 212. P. 163–168.

Chan K. A clinical trial gone awry: the Chocolate Happiness Undergoing More Pleasantness (CHUMP) study // Canadian Medical Association journal. 2007. December 4. Vol. 177. № 12. P. 1539–1541.

Schwartz M. A. The importance of stupidity in scientific research // Journal of cell science. 2008. June 1. Vol. 121. № 11. P. 1771.

Shafik A. Effect of different types of textiles on sexual activity. Experimental study // European urology. 1993. Vol. 24. № 3. P. 375–380.

Crowley P., Chalmers I., Keirse M. J. N. The effects of corticosteroid administration before preterm delivery: an overview of the evidence from controlled trials // British Journal of Obstetrics & Gynaecology. 1990. January. Vol. 97. № 1. P. 11–25.

Olson M. V. Precision medicine at the crossroads // Human genomics. 2017. Vol. 11. P. 23.

Windsor B., Popovich I., Jordan V., Showell M., Shea B., Farquhar C. Methodological quality of systematic reviews in subfertility: a comparison of Cochrane and non-Cochrane systematic reviews in assisted reproductive technologies // Human reproduction. 2012. December. Vol. 27. № 12. P. 3460–3466.

Fleming P. S., Seehra J., Polychronopoulou A., Fedorowicz Z., Pandis N. Cochrane and non-Cochrane systematic reviews in leading orthodontic journals: a quality paradigm? // The European Journal of Orthodontics. 2013. April. Vol. 35. № 2. P. 244–248.

Moseley A. M., Elkins M. R., Herbert R. D., Maher C. G., Sherrington C. Cochrane reviews used more rigorous methods than non-Cochrane reviews: survey of systematic reviews in physiotherapy // Journal of clinical epidemiology. 2009. October. Vol. 62. № 10. P. 1021–1030.

Olsen O., Middleton P., Ezzo J. et al. Quality of Cochrane reviews: assessment of sample from 1998 // BMJ. 2001. October. Vol. 323. № 7317. P. 829–832.

Clarke M., Chalmers I. Discussion sections in reports of controlled trials published in general medical journals // JAMA. 1998. Vol. 280. № 3. P. 280–282.

Clarke M., Hopewell S., Chalmers I. Reports of clinical trials should begin and end with up-to-date systematic reviews of other relevant evidence: a status report // Journal of the Royal Society of Medicine. 2007. April. Vol. 100. P. 187–190.

Fergusson D., Glass K. C., Hutton B., Shapiro S. Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? // Clinical Trials. 2005. June 1. Vol. 2. № 3. P. 218–232.

LeLorier J., Grégoire G., Benhaddad A., Lapierre J., Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials // The New England Journal of Medicine. 1997. August 21. Vol. 337. № 8. P. 536–542.

Amanullah S., Venkataraman R. The routine use of albumin for fluid resuscitation of critically ill patients is not warranted // Critical Care. 2004. December. Vol. 8. № 6.

Sauerland S., Maegele M. A CRASH landing in severe head injury // Lancet. 2004. October 9. Vol. 364. № 9442. P. 1291–1292.

Mirza R. D., Punja S., Vohra S., Guyatt G. The history and development of N of 1 trials // Journal of the Royal Society of Medicine. 2017. Vol. 110. № 8. P. 330–340.

Ioannidis J. P. A., Khoury M. J. Evidence-based medicine and big genomic data // Human Molecular Genetics. 2018. May 1. Vol. 27. № R 1. P. R2–7.

Lillie E. O., Patay B., Diamant J., Issell B., Topol E. J., Schork N. J. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? // Personalized medicine. 2011. March. Vol. 8. № 2. P. 161–173.

Moore A., Derry S., Eccleston C., Kalso E. Expect analgesic failure; pursue analgesic success // BMJ. 2013. Vol. 346. № 7911, f2690.

Wegman A., Van der Windt D. A., De Haan M., Deville W., Fo C., de Vries T. P. Switching from NSAIDs to paracetamol: a series of n of 1 trials for individual patients with osteoarthritis // Annals of the rheumatic diseases. 2003. December. Vol. 62. № 12. P. 1156–1161.

Mahon J. L., Laupacis A., Hodder R. V., McKim D. A., Paterson N. A., Wood T. E. et al. Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice // Chest. 1999. January. Vol. 115. № 1. P. 38–48.

Pope J. E., Prashker M., Anderson J. The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis // The Journal of Rheumatology. 2004. January. Vol. 31. № 1. P. 140–149.

Ledford H. Cancer-genome study challenges mouse “avatars” // Nature. 2017. October 9.

Lai Y., Wei X., Lin S., Qin L., Cheng L., Li P. Current status and perspectives of patient-derived xenograft models in cancer research // Journal of Hematology & Oncology. 2017. Vol. 10. P. 106.

Ferriss J. S., Rice L. W. The role of in vitro directed chemotherapy in epithelial ovarian cancer // Reviews in obstetrics & gynecology. 2010. Spring. Vol. 3. № 2. P. 49–54.

Burstein H. J., Mangu P. B., Somerfield M. R., Schrag D., Samson D., Holt L. et al. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays // Journal of clinical oncology. 2011. August 20. Vol. 29. № 24. P. 3328–3330.

Gebelhoff R. Sequencing the genome creates so much data we don’t know what to do with it // The Washington Post. 2015. July 7.

Goetz M. P., Kamal A., Ames M. M. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response // Clinical pharmacology and therapeutics. 2008. January. Vol. 83. № 1. P. 160–166.

Rubin R. Precision medicine: the future or simply politics? // JAMA. 2015. Vol. 313. № 11. P. 1089–1091.

Часть шестая

Lindsay G. B., Merrill R. M., Hedin R. J. The contribution of public health and improved social conditions to increased life expectancy: an analysis of public awareness // Journal of Community Medicine and Health Education. 2014. Vol. 4. P. 311.

Ten great public health Achievements – United States, 1900–1999 // MMWR. 1999. April 2. Vol. 48. № 12. P. 241–243.

Bunker J. P., Frazier H. S., Mosteller F. Improving health: measuring effects of medical care // The Milbank quarterly. 1994. Vol. 72. № 2. P. 225–258.

McKinley J. B., McKinley S. M. The questionable contribution of medical measures to the decline of mortality in the United States in the twentieth century // The Milbank Memorial Fund quarterly. Health and society. 1977. Summer. Vol. 55. № 3. P. 405–428.

Bunker J. P. The role of medical care in contributing to health improvements within societies // International Journal of Epidemiology. 2001. December 1. Vol. 30. № 6. P. 1260–1263.

Murray C. J. L. Why is Japanese life expectancy so high? // Lancet. 2011. September 24. Vol. 378. № 9797. P. 1124–1125.

Shiro Horiuchi Major causes of the rapid longevity extension in postwar Japan // The Japanese Journal of Population. 2011. March. Vol. 9. № 1. P. 162–171.

Crimmins E. M., Preston S. H., Cohen B. (eds) Explaining divergent levels of longevity in high-income countries. Washington (DC): National Academies Press (US), 2011.

Marmot M. G. Status syndrome: A challenge to medicine // JAMA. 2006. Vol. 295. № 11. P. 1304–1307.

Marmot M. The status syndrome: How social standing affects our health and longevity. New York, NY: Henry Holt and Company, 2004.

Marmot M. G., Rose G., Shipley M., Hamilton P. J. S. Employment grade and coronary heart disease in British civil servants // Journal of epidemiology and community health. 1978. Vol. 32. № 4. P. 244–249.

Adler N., Ostrove J. Socioeconomic status and health: what we know and what we don’t /Adler N., Marmot M., McEwen B., Stewart J. (eds.) Socioeconomic status and health in industrial nations. New York, NY: New York Academy of Sciences, 1999. P. 3–15.